← golden set
UNH
UNITEDHEALTH GROUP INCHealthcareanswer key
| field | SEC value | XBRL concept | printed on |
|---|---|---|---|
| Total revenue | $447.6B | Revenues | Total revenues |
| Operating income | $19.0B | OperatingIncomeLoss | Earnings from operations |
| Net income attributable to the company | $12.1B | NetIncomeLoss | Net earnings attributable to UnitedHealth Group common shareholders |
| Diluted EPS | $13.23 | EarningsPerShareDiluted | Diluted |
| Cash and cash equivalents | $24.4B | CashAndCashEquivalentsAtCarryingValue | Cash and cash equivalents |
| Total assets | $309.6B | Assets | Total assets · Total liabilities, redeemable noncontrolling interests and equity |
| Total liabilities | $207.9B | Liabilities | Total liabilities |
| Total shareholders' equity attributable to the company | - | not reported | not in this filing's XBRL |
| Net cash from operating activities | $19.7B | NetCashProvidedByUsedInOperatingActivities | Cash flows from operating activities |
| Net cash from investing activities | -$8.7B | NetCashProvidedByUsedInInvestingActivities | Cash flows used for investing activities |
| Net cash from financing activities | -$11.6B | NetCashProvidedByUsedInFinancingActivities | Cash flows used for financing activities |
Income statement
table #20 · score 51.3 vs 30 runner-up · in millions| For the Years Ended December 31, | |||
| (in millions, except per share data) | 2025 | 2024 | 2023 |
| Revenues: | |||
| Premiums | 352,229 | 308,810 | 290,827 |
| Products | 53,380 | 50,226 | 42,583 |
| Services | 38,038 | 36,040 | 34,123 |
| Investment and other income | 3,920 | 5,202 | 4,089 |
| Total revenues | 447,567 | 400,278 | 371,622 |
| Operating costs: | |||
| Medical costs | 313,995 | 264,185 | 241,894 |
| Operating costs | 59,592 | 53,013 | 54,628 |
| Cost of products sold | 50,655 | 46,694 | 38,770 |
| Depreciation and amortization | 4,361 | 4,099 | 3,972 |
| Total operating costs | 428,603 | 367,991 | 339,264 |
| Earnings from operations | 18,964 | 32,287 | 32,358 |
| Interest expense | (4,002) | (3,906) | (3,246) |
| Loss on sale of subsidiary and subsidiaries held for sale | (265) | (8,310) | - |
| Earnings before income taxes | 14,697 | 20,071 | 29,112 |
| Provision for income taxes | (1,890) | (4,829) | (5,968) |
| Net earnings | 12,807 | 15,242 | 23,144 |
| Earnings attributable to noncontrolling interests | (751) | (837) | (763) |
| Net earnings attributable to UnitedHealth Group common shareholders | 12,056 | 14,405 | 22,381 |
| Earnings per share attributable to UnitedHealth Group common shareholders: | |||
| Basic | 13.28 | 15.64 | 24.12 |
| Diluted | 13.23 | 15.51 | 23.86 |
| Basic weighted-average number of common shares outstanding | 908 | 921 | 928 |
| Dilutive effect of common share equivalents | 3 | 8 | 10 |
| Diluted weighted-average number of common shares outstanding | 911 | 929 | 938 |
| Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents | 12 | 6 | 6 |
Balance sheet
table #19 · score 52.5 vs 30.5 runner-up · in millions| (in millions, except per share data) | December 31,2025 | December 31,2024 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | 24,365 | 25,312 |
| Short-term investments | 3,756 | 3,801 |
| Accounts receivable, net of allowances of $1,208 and $985 | 23,018 | 22,365 |
| Other current receivables, net of allowances of $3,763 and $2,864 | 29,697 | 26,089 |
| Prepaid expenses and other current assets | 9,746 | 8,212 |
| Total current assets | 90,582 | 85,779 |
| Long-term investments | 54,251 | 52,354 |
| Property, equipment and capitalized software, net of accumulated depreciation and amortization of $7,546 and $6,971 | 10,762 | 10,553 |
| Goodwill | 110,499 | 106,734 |
| Other intangible assets, net of accumulated amortization of $7,472 and $8,350 | 20,474 | 23,268 |
| Other assets | 23,013 | 19,590 |
| Total assets | 309,581 | 298,278 |
| Liabilities, redeemable noncontrolling interests and equity | ||
| Current liabilities: | ||
| Medical costs payable | 39,337 | 34,224 |
| Accounts payable and accrued liabilities | 38,032 | 34,337 |
| Short-term borrowings and current maturities of long-term debt | 6,069 | 4,545 |
| Unearned revenues | 3,413 | 3,317 |
| Other current liabilities | 28,046 | 27,346 |
| Total current liabilities | 114,897 | 103,769 |
| Long-term debt, less current maturities | 72,320 | 72,359 |
| Deferred income taxes | 2,421 | 3,620 |
| Other liabilities | 18,245 | 15,939 |
| Total liabilities | 207,883 | 195,687 |
| Commitments and contingencies (Note 12) | ||
| Redeemable noncontrolling interests | 1,608 | 4,323 |
| Equity: | ||
| Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding | - | - |
| Common stock, $0.01 par value - 3,000 shares authorized; 906 and 915 issued and outstanding | 9 | 9 |
| Additional paid-in capital | 559 | - |
| Retained earnings | 95,603 | 96,036 |
| Accumulated other comprehensive loss | (2,061) | (3,387) |
| Nonredeemable noncontrolling interests | 5,980 | 5,610 |
| Total equity | 100,090 | 98,268 |
| Total liabilities, redeemable noncontrolling interests and equity | 309,581 | 298,278 |
Cash flow statement
table #23 · score 55 vs 16.3 runner-up · in millions| For the Years Ended December 31, | |||
| (in millions) | 2025 | 2024 | 2023 |
| Operating activities | |||
| Net earnings | 12,807 | 15,242 | 23,144 |
| Noncash items: | |||
| Depreciation and amortization | 4,361 | 4,099 | 3,972 |
| Deferred income taxes | (1,752) | (296) | (245) |
| Share-based compensation | 971 | 1,018 | 1,059 |
| Loss on sale of subsidiary and subsidiaries held for sale | 265 | 8,310 | - |
| Net gains on dispositions and other strategic transactions | (910) | (3,333) | (489) |
| Other, net | 1,673 | (28) | (16) |
| Net change in other operating items, net of effects from acquisitions and dispositions: | |||
| Accounts receivable | (764) | (1,437) | (3,114) |
| Other assets | (4,606) | (4,140) | (2,444) |
| Medical costs payable | 5,824 | 2,503 | 3,482 |
| Accounts payable and other liabilities | 1,665 | 2,463 | 3,516 |
| Unearned revenues | 163 | (197) | 203 |
| Cash flows from operating activities | 19,697 | 24,204 | 29,068 |
| Investing activities | |||
| Purchases of investments | (17,373) | (27,308) | (18,314) |
| Sales of investments | 9,288 | 18,514 | 7,307 |
| Maturities of investments | 8,446 | 9,319 | 9,230 |
| Cash paid for acquisitions and other transactions, net of cash assumed | (4,509) | (13,408) | (10,136) |
| Purchases of property, equipment and capitalized software | (3,622) | (3,499) | (3,386) |
| Loans to care providers - cyberattack | - | (9,033) | - |
| Repayments of care provider loans - cyberattack | 1,680 | 4,514 | - |
| Cash received from dispositions and other strategic transactions, net | 561 | 2,041 | 685 |
| Originations and purchases of loans | (4,795) | (2,477) | (1,664) |
| Repayments and maturities of loans | 1,980 | 908 | 613 |
| Other, net | (341) | (98) | 91 |
| Cash flows used for investing activities | (8,685) | (20,527) | (15,574) |
| Financing activities | |||
| Common share repurchases | (5,545) | (9,000) | (8,000) |
| Cash dividends paid | (7,916) | (7,533) | (6,761) |
| Proceeds from common stock issuances | 827 | 1,846 | 1,353 |
| Repayments of long-term debt | (3,050) | (3,000) | (2,125) |
| Proceeds from (repayments of) short-term borrowings, net | 807 | (151) | 11 |
| Proceeds from issuance of long-term debt | 2,969 | 17,811 | 6,394 |
| Customer funds administered | 366 | (1,560) | (521) |
| Purchases of redeemable noncontrolling interests | (165) | (280) | (730) |
| Other, net | 63 | (1,645) | (1,150) |
| Cash flows used for financing activities | (11,644) | (3,512) | (11,529) |
| Effect of exchange rate changes on cash and cash equivalents | 40 | (61) | 97 |
| (Decrease) increase in cash and cash equivalents, including cash within businesses held for sale | (592) | 104 | 2,062 |
| Less: net increase in cash within businesses held for sale | (355) | (219) | - |
| Net (decrease) increase in cash and cash equivalents | (947) | (115) | 2,062 |
| Cash and cash equivalents, beginning of period | 25,312 | 25,427 | 23,365 |
| Cash and cash equivalents, end of period | 24,365 | 25,312 | 25,427 |
| Supplemental cash flow disclosures | |||
| Cash paid for interest | 4,030 | 3,594 | 3,035 |
| Cash paid for income taxes | 3,714 | 4,620 | 6,078 |